Convertible bond principal; neither IPO net proceeds nor the 2025 placement amount.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY IFRS / consolidated
802,623,000
123,747,000 Net income attributable to owners of the parent
Consolidated group figures include proprietary products and other businesses and are not equivalent to the CRO/CDMO segment.
Adjusted earnings represent non-IFRS group net income/(loss), not the PRC parent-attributable measure excluding nonrecurring items, and must not be mixed with reported parent-attributable earnings.
Parent-attributable results moved to profit from a loss in 2024; fair value changes and other income affect group earnings.
publishedAt is the annual results announcement date. reportUrl links to the subsequently issued full annual report; its actual publication date was not individually verified.
2026H1 · Reporting notes
Consolidated group figures include proprietary products and other businesses and are not equivalent to the CRO/CDMO segment.
Adjusted earnings represent non-IFRS group net income/(loss), not the PRC parent-attributable measure excluding nonrecurring items, and must not be mixed with reported parent-attributable earnings.
Parent-attributable results moved from prior-period profit to loss. Total revenue retains the reported -23.9% year-over-year change, rather than the 73.8% figure excluding one-time items.
publishedAt is the interim results announcement date. reportUrl links to the full interim report; its actual publication date was not individually verified.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
PepiX™ connects AI, automated synthesis, and experimental screening. The website identifies oral cyclic peptides as a priority; food-peptide GRAS status is not pharmaceutical evidence.
The solid-state platform combines prediction and experiments and offers a dedicated crystal structure determination service.
The structure determination page lists small-molecule drugs, salts, cocrystals, mixtures, and structural isomers and discloses a Glacios 200 kV platform.
XtalGazer uses prediction and experiments for solid-form selection. Experimental and computational evidence must be distinguished for each project.
Original 2025 and 2026 interim earnings announcements disclose drug-discovery solutions revenue and group results.
Listed entity HKEX 2228; financials are consolidated group figures.
Program / service
Target / indication
Representative stage
Evidence & scope
PepiX™ oral cyclic peptide research
Not disclosed · Not disclosed
未披露
Quantitative human results not confirmed in this review
Solid-state R&D capabilities
Determined by the submitted sample and research question · Not applicable; service capability
Services / platform
Not applicable; not a human clinical program
MicroED / 3D ED service capabilities
Determined by the submitted sample and research question · Not applicable; service capability
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
Public information reviewed is insufficient to reconstruct the complete formulation, absolute bioavailability, variability, or food effects.
Public sources confirm service availability. Sample suitability, scope of work, pricing, turnaround time, success criteria, and the quality system require direct confirmation.
This record describes service capabilities, not the clinical progress of a drug candidate or an independent validation of service success rates.
Website throughput and speed figures are company-reported and do not guarantee success rates or delivery times for all samples.
MicroED refinement, the scope of CSP support, report quality, raw data, and the execution site require confirmation in the scope of work.
The group does not separately disclose all CRO/CDMO profit on a directly comparable basis; group valuation or profit should not directly determine assessments of this business.
